Conceivable's New Guard: The Strategic Play to Automate the IVF Industry

NEW YORK, NY – July 20, 2026 – In the world of high-stakes biotech, personnel announcements are often more than just a change on the masthead; they are a declaration of intent. Conceivable Life Sciences’ appointment of Julie O'Shaughnessy as President and Vincent Payet as SVP of U.S. Deployment & Partner Success is precisely that. The move, announced today, is not merely about strengthening a leadership team. It is the critical placement of seasoned operators with a specific mandate: to execute the U.S. commercial launch of the company’s automation-assisted IVF platform, AURA, and to cement its foundational partnership with fertility giant IVI RMA Global. For a company aiming to industrialize one of the most artisanal fields of medicine, these hires are the story behind the strategy.

The Architects of Scale

To understand the significance of these appointments, one must look beyond the titles to the track records. Julie O'Shaughnessy is not a conventional biotech executive; she is a specialist in hyper-growth and operational scaling. Her most recent role as COO at Vivodyne saw her building a next-generation drug discovery platform at the complex intersection of biology, automation, and AI. Before that, her time at bio-manufacturing firm Resilience was defined by helping scale the organization from a startup into a 2,000-employee powerhouse valued at $2.5 billion. This is the experience Conceivable has recruited—not just to launch a product, but to build an empire.

As Conceivable’s CEO and Co-Founder, Alan Murray, stated, “We built AURA to standardize the IVF laboratory. Getting that right at scale requires a leadership team with real depth in operations and clinical partnerships.” O'Shaughnessy’s background in scaling complex, multi-site operations is the operational depth Murray speaks of. She is tasked with translating AURA's technological promise into a repeatable, reliable, and globally expanding commercial reality.

Complementing her is Vincent Payet, a 13-year veteran of Ferring Pharmaceuticals, who most recently served as CEO for its North Latin America division. Holding a PhD in Molecular and Cellular Biology, Payet brings a rare blend of deep scientific understanding and extensive commercial leadership within a global pharmaceutical framework. His role is to manage the intricate dance of clinical deployment and partner success, starting with the linchpin IVI RMA relationship. His personal dedication to the fertility space, having built his own family through surrogacy, adds a layer of conviction that is invaluable in this mission-driven sector.

Together, they represent the two pillars required for Conceivable's success: O'Shaughnessy builds the engine of expansion, while Payet ensures it integrates seamlessly with the clinical world it's meant to serve.

AURA: The Technology Behind the Ambition

The strategy these new leaders are hired to execute revolves around AURA, a platform Conceivable describes as the world's first automation-assisted IVF lab. This is not mere incremental improvement; it is a fundamental re-imagining of a process that has remained largely manual and artisanal for decades. AURA integrates advanced robotics, machine vision, and AI to perform over 200 operator-dependent steps in the IVF workflow—from finding eggs in follicular fluid to the delicate process of intracytoplasmic sperm injection (ICSI).

Leveraging technologies adapted from semiconductor manufacturing and autonomous vehicles, the system achieves sub-micron precision, a level of consistency impossible for the human hand to replicate over thousands of procedures. It employs Optical Coherence Tomography (OCT), a non-invasive imaging technique, to provide three-dimensional views of embryos, reducing the risk of damage during critical manipulations. A peer-reviewed proof-of-concept study published in late 2025 validated the approach, documenting a 64.3% fertilization rate and the birth of five healthy babies from twelve embryo transfers performed by the system under human supervision.

Crucially, AURA is not designed to replace embryologists but to augment them. As Dr. Alejandro Chavez-Badiola, the company's Co-Founder and Chief Medical and Innovation Officer, noted, “Every patient deserves the same standard of care... AURA makes that possible technically. Julie and Vincent make it happen operationally.” The platform’s proprietary data flywheel, which learns from every cycle to continuously refine its process, promises a future where outcomes are not just standardized but constantly improving. This allows embryologists to shift their focus from repetitive manual tasks to critical clinical decision-making, effectively multiplying their expertise.

The IVI RMA Partnership: A Blueprint for Market Dominance

Technology, no matter how revolutionary, is useless without a path to market. Conceivable secured that path earlier this month with its landmark partnership with IVI RMA Global, the world’s largest fertility care organization. The deal includes a strategic investment from IVI RMA and a board seat for its Executive Chairman, Prof. Antonio Pellicer, signaling deep alignment.

The plan is to deploy AURA in an initial U.S. clinic in 2027 before expanding across IVI RMA's vast global network. For IVI RMA, the partnership is a strategic move to standardize quality control and reduce variability across its centers, reinforcing its position as a market leader. For Conceivable, it provides immediate access, credibility, and a scalable channel for deployment that would otherwise take years, if not decades, to build.

This is where the new leadership becomes indispensable. Executing a rollout of this magnitude requires a team that understands both the operational complexities of rapid scaling (O'Shaughnessy) and the nuances of clinical partnerships within a global healthcare network (Payet). They are the operational bridge between Conceivable’s technology and IVI RMA’s clinical infrastructure.

Reshaping the Fertility Landscape

Conceivable's strategy is a direct response to the systemic pressures facing the IVF industry. With a global shortage of skilled embryologists—a “workforce crisis”—and a demand for IVF that outstrips supply by more than tenfold, the current manual model is unsustainable. Automation is seen by many industry analysts as inevitable.

While competitors like Overture Life are also pursuing automation and firms like Vitrolife focus on specific workflow tools, Conceivable’s bet is on its end-to-end, fully integrated platform. The goal is not just to improve success rates but to fundamentally alter the economics of fertility care. By increasing efficiency and reducing the number of cycles needed per live birth, the company claims it can significantly lower the cost per baby, a critical step toward expanding access beyond the fraction of the population that can currently afford it.

Of course, the path is not without challenges. Critics raise valid concerns about the potential for systemic errors, data privacy, and ensuring that cost savings are passed on to patients rather than just bolstering clinic profits. Yet, the appointments of O'Shaughnessy and Payet, combined with the strategic backing of IVI RMA, signal that Conceivable is moving from a theoretical concept to a full-fledged commercial operation, ready to tackle these challenges head-on. The assembly of this team suggests the company is no longer just developing a technology; it is building the corporate machine to dominate the next era of fertility care.